Lipoprotein lipase HindIII polymorphism influences HDL-cholesterol levels in statin-treated patients with coronary artery disease

Wiener Klinische Wochenschrift

Volumn 119, Issue 15-16, 2007, Pages 476-482

  Javorský, Martin ^a   Gašperíková, Daniela ^b   Ukropec, Jozef ^b   Sedláková, Barbora ^c   Riečanský, Igor ^d   Križanová, Ol'ga ^c   Šeböková, Elena ^b   Dobríková, Martina ^a   Klimeš, Iwar ^b   Tkáč, Ivan ^a,e  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c INSTITUTE OF MOLECULAR PHYSIOLOGY AND GENETICS   (Slovakia)

^d NATIONAL INSTITUTE OF CARDIOVASCULAR DISEASES   (Slovakia)

^e L PASTEUR UNIVERSITY HOSPITAL   (Slovakia)

Author keywords

Coronary artery disease; HDL cholesterol; HindIII polymorphism; Lipoprotein lipase gene; Statin

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; TYPE II SITE SPECIFIC DEOXYRIBONUCLEASE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 34548523393     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-007-0824-1     Document Type: Article

References (30)

1. Lewis GF, Rader DJ (2005) New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96: 1221-1232
2. Merkel M, Eckel RH, Goldberg IJ (2002) Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43: 1997-2006
3. Mead JR, Irvine SA, Ramji DP (2002) Lipoprotein lipase: structure, function, regulation, and role in disease. J Mol Med 80: 753-769
4. Duffy D, Rader DJ (2006) Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 113: 1140-1150
5. Costanza MC, Cayanis E, Ross BM, Flaherty MS, Alvin GB, Morabia A, et al (2005) Relative contributions of genes, environment, and interactions to blood lipid concentrations in a general adult population. Am J Epidemiol 161: 714-724
6. Caslake MJ, Packard CJ (2004) Phenotypes, genotypes and response to statin therapy. Curr Opin Lipidol 15: 387-392
7. Schaefer EJ, Asztalos BF (2006) The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 8: 41-49
8. Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, et al (2004) Atorvastatin improves diabetic dyslipidemia and increases lipoprotein Lipase activity in vivo. Atherosclerosis 175: 325-331
9. Isley WL, Miles JM, Patterson BW, Harris WS (2006) The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus. J Lipid Res 47: 193-200
10. Boekholdt SM, Souverein OW, Tanck MW, Hovingh GK, Kuivenhoven JA, Jukema JW (2006) Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL-cholesterol levels. Clin Genet 69: 263-270
11. Gotoda T, Yamada N, Murase T, Shimano H, Shimada M, Harada K, et al (1992) Detection of three separate DNA polymorphisms in the human lipoprotein lipase gene by gene amplification and restriction endonuclease digestion. J Lipid Res 33: 1067-1072
12. Ahn YI, Kamboh MI, Hamman RF, Cole SA, Ferrell RE (1993) Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease. J Lipid Res 34: 421-428
13. Anderson JL, King GJ, Bair TL, Elmer SP, Muhlestein JB, Habashi J, et al (1999) Association of lipoprotein lipase gene polymorphisms with coronary artery disease. J Am Coll Cardiol 33: 1013-1020
14. Socquard E, Durlach A, Clavel C, Nazeyrollas P, Durlach V (2006) Association of HindIII and PvuII genetic polymorphisms of lipoprotein lipase with lipid metabolism and macrovascular events in type 2 diabetic patients. Diabetes Metab 32: 262-269
15. Radha V, Mohan V, Vidya R, Ashok AK, Deepa R, Mathias RA (2006) Association of lipoprotein lipase HindIII and Ser447Ter polymorphisms with dyslipidemia in Asian Indians. Am J Cardiol 97: 1337-1342
16. Larson I, Hoffmann MM, Ordovas JM, Schaefer EJ, Marz W, Kreuzer J (1999) The LPL HindIII RFLP: association with TC and LDL-C, but not with HDL-C and TG in 342 females. Clin Chem 45: 963-968
17. Alberti KGMM, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional Report of a WHO Consultation. Diabet Med 15: 539-553
18. Rip J, Nierman MC, Ross CJ, Jukema JW, Hayden MR, Kastelein JJ, et al (2006) Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol 26: 1236-1245
19. Saiki A, Murano T, Watanabe F, Oyama T, Miyashita Y, Shirai K (2005) Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J Atheroscler Thromb 12: 163-168
20. Bey L, Maigret P, Laouenan H, Hamilton MT (2002) Induction of lipoprotein lipase gene expression in 3T3-L1 preadipocytes by atorvastatin, a cholesterol- and triglyceride-lowering drug. Pharmacology 66: 51-56
21. Sato A, Watanabe K, Fukuzumi H, Hase K, Ishida F, Kamei T (1991) Effect of simvastatin (MK-733) on plasma triglyceride levels in rats. Biochem Pharmacol 41: 1163-1172
22. Verd JC, Peris C, Alegret M, Diaz C, Hernandez G, Vazquez M, et al (1999) Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Br J Pharmacol 127: 1479-1485
23. Schoonjans K, Peinado-Onsurbe J, Fruchart JC, Tailleux A, Fievet C, Auwerx J (1999) 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein C-III and lipoprotein lipase. FEBS Lett 452: 160-164
24. Endo K, Miyashita Y, Saiki A, Oyama T, Koide N, Ozaki H, et al (2004) Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb 11: 341-347
25. Goodarzi MO, Taylor KD, Scheuner MT, Antoine HJ, Guo X, Shah PK, et al (2006) Haplotypes in the lipoprotein lipase gene influence high-density lipoprotein cholesterol response to statin therapy and progression of atherosclerosis in coronary artery bypass grafts. Pharmacogenomics J [Epub ahead of print]
26. Kastelein JJ, Jukema JW, Zwinderman AH, Clee S, van Boven AJ, Jansen H, et al (2000) Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group. Circulation 102: 1629-1633
27. Sing K, Ballantyne CM, Ferlic L, Brugada R, Cushman I, Dunn JK, et al (1999) Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. Atherosclerosis 144: 435-442
28. Thompson JF, Man M, Johnson KJ, Wood LS, Lira ME, Lloyd DB, et al (2005) An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 5: 352-358
29. Kasim SE, LeBoeuf RC, Khilnani S, Tallapaka L, Dayananda D, Jen KL (1992) Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat. J Lipid Res 33: 1-7
30. Sasaki J, Yamamoto K, Kobori S, Setoguchi Y, Sato Y, Matsunaga A, et al (1995) Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients. Int J Clin Pharmacol Ther 33: 420-426